Faisal Mehmud, Chief Medical Officer of Medicus Pharma Ltd. (NASDAQ:MDCX), filed a Form 4 on November 17, 2026, disclosing the acquisition of 14,534 common shares on November 13, 2026, through a private placement subscription agreement.

Key Highlights

  • Reporting person: Faisal Mehmud, Chief Medical Officer of Medicus Pharma Ltd.
  • Transaction date: November 13, 2026, via a subscription agreement with the issuer.
  • Shares acquired: 14,534 common shares, no par value, at a purchase price of $1.72 per share.
  • Transaction type: Acquisition (Code A) in a private placement in which other investors also participated under separate subscription agreements.
  • Resulting ownership: Mehmud directly holds 43,946 common shares following the transaction.

Mehmud's Private Placement Purchase of Medicus Pharma Common Shares

According to the Form 4 filed with the SEC on November 17, 2026, Faisal Mehmud, serving as Chief Medical Officer of Medicus Pharma Ltd., acquired 14,534 common shares, no par value, at $1.72 per share on November 13, 2026. The filing identifies the transaction code as "A" (acquisition) and classifies the ownership as direct.

The filing's explanation of responses states: "On November 13, 2026, Faisal Mehmud entered into a subscription agreement with the Issuer, pursuant to which Mr. Mehmud agreed to purchase 14,534 common shares, no par value, at a purchase price of $1.72 per share in a private placement in which other investors also participated under separate subscription agreements." No derivative securities transactions were reported in Table II of the filing.

Following the reported transaction, Mehmud's direct beneficial ownership of Medicus Pharma common shares stands at 43,946, according to the filing. The Form 4 was signed by Raza Bokhari as Attorney-in-Fact for Faisal Mehmud and dated November 17, 2026.

What Was Disclosed

Medicus Pharma Ltd.'s Chief Medical Officer, Faisal Mehmud, reported the purchase of 14,534 common shares at $1.72 per share through a private placement subscription agreement dated November 13, 2026, bringing his direct beneficial ownership to 43,946 shares.